138 related articles for article (PubMed ID: 36989466)
1. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin.
Ishihara S; Ogura K; Maejima A; Shimoi T; Sudo K; Kojima Y; Fukushima S; Osaki S; Kobayashi E; Iwata S; Matsui Y; Yonemori K; Kawai A
Jpn J Clin Oncol; 2023 Jun; 53(6):494-500. PubMed ID: 36989466
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
3. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
4. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
Shimada E; Endo M; Matsumoto Y; Tsuchihashi K; Ito M; Kusaba H; Nabeshima A; Nawata T; Maekawa A; Matsunobu T; Setsu N; Fujiwara T; Iida K; Nakagawa M; Hirose T; Kanahori M; Oyama R; Isobe T; Ariyama H; Kohashi K; Yamamoto H; Oda Y; Iwamoto Y; Akashi K; Baba E; Nakashima Y
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768491
[TBL] [Abstract][Full Text] [Related]
5. Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma.
Sato Y; Nakano K; Wang X; Fukuda N; Urasaki T; Ohmoto A; Hayashi N; Yunokawa M; Ono M; Tomomatsu J; Saito M; Minami Y; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944888
[TBL] [Abstract][Full Text] [Related]
6. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
[TBL] [Abstract][Full Text] [Related]
7. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
[TBL] [Abstract][Full Text] [Related]
8. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
[TBL] [Abstract][Full Text] [Related]
9. Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Kawaguchi K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Hayashi N; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Cancer Diagn Progn; 2021; 1(4):303-308. PubMed ID: 35403143
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Takamizawa S; Shimoi T; Satomi-Tsushita N; Yazaki S; Okuya T; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Yonemori K
BMC Cancer; 2022 Jan; 22(1):64. PubMed ID: 35027011
[TBL] [Abstract][Full Text] [Related]
11. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
12. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
[TBL] [Abstract][Full Text] [Related]
13. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
15. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types.
Morisaki T; Kashiwagi S; Asano Y; Goto W; Takada K; Ishihara S; Shibutani M; Tanaka H; Hirakawa K; Ohira M
World J Surg Oncol; 2021 Nov; 19(1):324. PubMed ID: 34775950
[TBL] [Abstract][Full Text] [Related]
16. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
Tsuchihashi K; Kusaba H; Yoshihiro T; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Imajima T; Shinohara Y; Ito M; Yamaga S; Tanoue K; Arimizu K; Ohmura H; Hanamura F; Yamaguchi K; Isobe T; Ariyama H; Nakashima Y; Akashi K; Baba E
Sci Rep; 2020 Dec; 10(1):20896. PubMed ID: 33262403
[TBL] [Abstract][Full Text] [Related]
17. Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
Koyama Y; Kawai S; Uenaka N; Okazaki M; Asaoka M; Teraoka S; Ueda AI; Miyahara K; Kawate T; Kaise H; Yamada K; Ishikawa T
Cancer Diagn Progn; 2021; 1(5):435-441. PubMed ID: 35403160
[TBL] [Abstract][Full Text] [Related]
18. Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin.
Kobayashi H; Okuma T; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Goto T; Tanaka S
J Orthop Sci; 2022 Jan; 27(1):222-228. PubMed ID: 33384219
[TBL] [Abstract][Full Text] [Related]
19. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
Takahashi M; Inoue K; Mukai H; Yamanaka T; Egawa C; Miyoshi Y; Sakata Y; Muramoto K; Ikezawa H; Matsuoka T; Tsurutani J
Breast Cancer; 2021 Jul; 28(4):945-955. PubMed ID: 33677779
[TBL] [Abstract][Full Text] [Related]
20. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
